Transport of six tyrosine kinase inhibitors: active or passive?

Transport of six tyrosine kinase inhibitors: active or passive?

Transport of erlotinib, gefitinib, sorafenib, sunitinib, dasatinib and crizotinib can be active or passive, which was studied by measuring uptake at low (4 °C; passive) and normal temperature (37 °C; active and passive) and by the use of specific organic cation transporter (OCT) inhibitors. Intrace...

Full description

Bibliographic Details
Main Authors:	Richard J. Honeywell, Sarina Hitzerd, Ietje Kathmann, Godefridus J. Peters
Format:	Article
Language:	English
Published:	International Association of Physical Chemists (IAPC) 2016-03-01
Series:	ADMET and DMPK
Online Access:	http://pub.iapchem.org/ojs/index.php/admet/article/view/275

Similar Items

Subcellular localization of several structurally different tyrosine kinase inhibitors
by: Richard Honeywell, et al.
Published: (2018-09-01)

Adaptation of a human gut epithelial model in relation to the assessment of clinical pharmacokinetic parameters for selected tyrosine kinase inhibitors
by: Richard Honeywell, et al.
Published: (2015-03-01)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
by: Richard J. Honeywell, et al.
Published: (2020-11-01)

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance
by: Daniel J. de Klerk, et al.
Published: (2018-12-01)

ADME/DMPK in the development and use of tyrosine and serine-threonine kinase inhibitors
by: Godefridus J. Peters, et al.
Published: (2016-10-01)

Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro
by: Godefridus J. Peters, et al.
Published: (2020-10-01)

RX-3117 (Fluorocyclopentenyl-Cytosine)-Mediated Down-Regulation of DNA Methyltransferase 1 Leads to Protein Expression of Tumor-Suppressor Genes and Increased Functionality of the Proton-Coupled Folate Carrier
by: Dzjemma Sarkisjan, et al.
Published: (2020-04-01)

Folate homeostasis of cancer cells affects sensitivity to not only antifolates but also other non-folate drugs: effect of MRP expression
by: Peters Godefridus J., et al.
Published: (2013-06-01)

TYROSINE KINASE INHIBITORS AND INTERFERON
by: Maria Dimou, et al.
Published: (2014-01-01)

Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance
by: Nagaraju Anreddy, et al.
Published: (2014-09-01)

Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease
by: John J. Ryan, MD
Published: (2016-12-01)

Tissue distribution of crizotinib and gemcitabine combination in a patient-derived orthotopic mouse model of pancreatic cancer
by: Richard J. Honeywell, et al.
Published: (2016-12-01)

ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro
by: Skoglund K, et al.
Published: (2013-08-01)

Anti-inflammatory activity of repurposed tyrosine kinase inhibitors in macrophages
by: Chaffey, L
Published: (2023)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
by: Xu H, et al.
Published: (2019-07-01)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
by: Huang JT, et al.
Published: (2022-11-01)

Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance
by: Yi-Jun Wang, et al.
Published: (2014-09-01)

Effect of tyrosine kinase inhibitors on the cytotoxic activity against HIV-1 infection
by: S. Rodríguez-Mora, et al.
Published: (2017-12-01)

Bruton’s Tyrosine Kinase Inhibitors: Recent Updates
by: Amneh Fares, et al.
Published: (2024-02-01)

Tyrosine Kinase Inhibitors Target B Lymphocytes
by: Nikki Lyn Esnardo Upfold, et al.
Published: (2023-02-01)

Spheroacanthocytes secondary to novel tyrosine kinase inhibitors
by: Michael Ashby, et al.
Published: (2020-11-01)

Targeting tumour microenvironment by tyrosine kinase inhibitor
by: Hor-Yue Tan, et al.
Published: (2018-02-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
by: Yi-fan Chen, et al.
Published: (2011-12-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015-09-01)

Second-generation inhibitors of Bruton tyrosine kinase
by: Jingjing Wu, et al.
Published: (2016-09-01)

Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer
by: Nikolaos Dervisis, et al.
Published: (2016-01-01)

Tyrosine kinase inhibitor Tofacitinib. Safety issues
by: G. V. Lukina, et al.
Published: (2015-12-01)

Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System
by: Skubalova Z, et al.
Published: (2021-01-01)

Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
by: Avadhut D Joshi, et al.
Published: (2012-01-01)

Phenylpyrazalopyrimidines as Tyrosine Kinase Inhibitors: Synthesis, Antiproliferative Activity, and Molecular Simulations
by: Bhupender S. Chhikara, et al.
Published: (2020-05-01)

Tyrosine Kinase Inhibitors Display Potent Activity against Cryptosporidium parvum
by: Maria G. Nava, et al.
Published: (2023-02-01)

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
by: Nelson V, et al.
Published: (2013-03-01)

Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
by: Yu Yao, et al.
Published: (2023-01-01)

The two facets of receptor tyrosine kinase in cardiovascular calcification—can tyrosine kinase inhibitors benefit cardiovascular system?
by: Ainun Nizar Masbuchin, et al.
Published: (2022-09-01)

The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of Tyrosine Kinase Inhibitors
by: Fangrui Xiu, et al.
Published: (2023-01-01)

Transport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritis.
by: Christian Schmidt-Lauber, et al.
Published: (2012-01-01)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
by: Obada Ababneh, et al.
Published: (2022-05-01)

Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors
by: Jiangnan Liu, et al.
Published: (2024-03-01)

Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa
by: Ahmad Assi, et al.
Published: (2023-12-01)

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
by: Peng Zeng, et al.
Published: (2020-09-01)